Phase I Study of Novel Drug Shows Preliminary Activity in Mesothelin-Expressing Tumors

March 30, 2020 10:00 am

NEW YORK – Data from a Phase I study published last week in the Journal of Clinical Oncology showed that Bayer’s investigational compound anetumab ravtansine (BAY 94-9343), an antibody-drug conjugate comprising an anti-mesothelin antibody linked to maytansinoid DM4, was well … Read more